menu
    • menu

    Company profile for Telomir Pharmaceuticals

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Telomir Pharmaceuticals, Inc. is a pharmaceutical firm in pre-clinical stages, concentrating on Telomir-1's development and marketing. Telomir-1 is a pioneering small molecule designed to extend telomere caps, protecting DNA and potentially reversing age-related ailments. Telomeres, composed of DNA and proteins, safeguard chromosome ends. Aging leads to telomere shortening, accelerated by metal reactivity, heightening vulnerab...
    Telomir Pharmaceuticals, Inc. is a pharmaceutical firm in pre-clinical stages, concentrating on Telomir-1's development and marketing. Telomir-1 is a pioneering small molecule designed to extend telomere caps, protecting DNA and potentially reversing age-related ailments. Telomeres, composed of DNA and proteins, safeguard chromosome ends. Aging leads to telomere shortening, accelerated by metal reactivity, heightening vulnerability to degenerative diseases. Telomir aims to launch Telomir-1 orally for hemochromatosis and eventually for post-chemotherapy recovery and various age-related inflammatory conditions like osteoarthritis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Telomir PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Baltimore, Maryland 21205
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://telomirpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/telomir-pharmaceuticals-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Telomir Pharma Reports Favorable IND Safety for Telomir-1
    Telomir Pharma Reports Favorable IND Safety for Telomir-1

    18 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-18/telomir-pharmaceuticals-reports-favorable-ind-enabling-glp-safety-results-for-telomir-1-supporting-f

    PHARMIWEB
    18 Dec 2025
    Share Share
    Telomir Pharma Reveals Telomir-1 Reduces PSA In Prostate Cancer
    Telomir Pharma Reveals Telomir-1 Reduces PSA In Prostate Cancer

    25 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-25/telomir-pharmaceuticals-reports-new-data-showing-telomir-1-significantly-reduces-psa-levels-in-human

    PHARMIWEB
    25 Nov 2025
    Share Share
    Telomir Pharma Reveals Telomir-1 Eradicates Aggressive Leukemia
    Telomir Pharma Reveals Telomir-1 Eradicates Aggressive Leukemia

    21 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-21/telomir-pharmaceuticals-announces-telomir-1-kills-aggressive-human-leukemia-cells

    PHARMIWEB
    21 Nov 2025
    Share Share
    Telomir-1 Beats DFO in Cutting Intracellular Iron Levels
    Telomir-1 Beats DFO in Cutting Intracellular Iron Levels

    12 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-12/telomir-pharmaceuticals-reports-telomir-1-outperforms-fda-approved-gold-standard-iron-chelator-defer

    PHARMIWEB
    12 Nov 2025
    Share Share
    Telomir Pharma Unveils Telomir-1's Superiority Over Rapamycin
    Telomir Pharma Unveils Telomir-1's Superiority Over Rapamycin

    23 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-23/telomir-pharmaceuticals-reports-new-data-showing-telomir-1-resets-cancers-kill-and-clean-defense

    PHARMIWEB
    23 Oct 2025
    Share Share
    Telomir Data Shows Telomir-1 Kills Aggressive Pancreatic Cancer
    Telomir Data Shows Telomir-1 Kills Aggressive Pancreatic Cancer

    14 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-14/telomir-pharmaceuticals-announces-new-data-showing-that-telomir-1-kills-aggressive-pancreatic-cancer

    PHARMIWEB
    14 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search